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Abstract—Hyperglycaemia is prevalent in critical care and 
tight control can reduce mortality from 9-43% depending on 
the level of control and the cohort. This research presents a 
table-based method that varies both insulin dose and 
nutritional input to achieve tight control. The system mimics a 
previously validated model-based system, but can be used for 
long term, large patient number clinical evaluation. This paper 
evaluates this method in simulation using retrospective data 
and then compares clinical measurements over 15,000 patient 
hours to validate the models and development approach. This 
validation thus also validates the in silico comparison to the 
landmark clinical tight glycaemic control protocols. Overall, an 
average clinical glucose level is 5.9 ± 1.0 mmol/L, matching 
simulation, however the overall clinical glucose distribution is 
slightly tighter than that obtained in simulation, indicating that 
the retrospective virtual trial design approach is slightly 
conservative. Finally, the model based approach is shown to 
have tighter control than existing, more ad-hoc clinical 
approaches based on the simulation results that qualitatively 
match reported clinical results, but also show significant 
variation around the average levels obtained in both the hypo- 
and hyper- glycaemic ranges. 
I. INTRODUCTION 
Stress induced hyperglycaemia is prevalent in critical 
care, and can occur in patients with no history of diabetes [1, 
2]. Critically ill patients exhibit increased endogenous 
glucose production, erratic insulin production and increased 
insulin resistance. Therefore, enteral feeding of glucose and 
administration of glucocorticoids can further enhance the 
onset of hyperglycaemia and insulin resistance respectively. 
Hyperglycaemia also worsens outcomes leading to risk of 
further complications such as polyneuropathy and multiple 
organ failure [2]. van den Berghe et al [2, 3] showed that 
tight glucose control averaging 6.1mmo/L reduced mortality 
up to 45%. Krinsley [4] showed a 17-29% reduction with a 
higher glucose average of 7.75mmol/L. 
Model-based protocols for insulin-mediated glucose 
control in critical care have shown promise, but can have 
limitations [5]. Due to increased insulin resistance and 
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insulin effect saturation [6], only limited glycaemic 
reductions can be made using insulin alone [7]. Hence, the 
only avenue left to control blood glucose is to also control 
the exogenous nutritional input that exacerbates stress 
induced hyperglycaemia [8].  
This paper presents the model based development of a 
robust, table-based protocol (“SPRINT” – Specialized 
Relative Insulin Nutrition Tables) to maintain blood glucose 
levels in the target band of 4-6.1 mmol/L [9]. This protocol 
has been developed based on computerized glycaemic 
control trials and patient simulations using a physiologically 
verified insulin-glucose system model. Clinical results are 
also compared to these simulations to validate the design 
approach and to compare to other clinical protocols [2-4].  
II. METHODS 
A. System Model 
Tight Glucose control requires capturing the fundamental 
dynamics of the glucose regulatory system. Chase et al. [5-
7,9] used the system model defined: 
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where G(t) [mmol/L] is the plasma glucose above an 
equilibrium level, GE [mmol/L]. I(t) [mmol/L] is plasma 
insulin concentration resulting from exogenous insulin 
input, uex(t) [mU/min]. Q(t) [mU/L] is interstitial insulin 
concentration and k [1/min] accounts for the effective life of 
insulin in the system. Patient endogenous glucose clearance 
and insulin sensitivity are pG [1/min] and SI [L/(mU.min)], 
respectively. V [L] is the insulin distribution volume and n 
[1/min] is the constant first order decay rate for insulin from 
plasma.  Total plasma glucose input is denoted P(t) 
[mmol/(L.min)]. kpr is the rise rate of rate of plasma glucose 
input from enterally administered feed [1/min]. kpd is the 
decay rate of rate of glucose input into plasma from enterally 
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administered feed [1/min]. iP , 1+iP  are stepwise 
consecutive enteral glucose feed rates [mmol/L.min]. 
Michaelis-Menten functions are used to model saturation, 
with αI [L/mU] used for the saturation of plasma insulin 
disappearance, and αG [L/mU] for the saturation of insulin-
dependent glucose clearance. For the simulations in this 
study, k, n, G, I and V are set to generic population values 
[5-7]. 
Patient specific profiles for time-varying SI and pG can be 
created by fitting retrospective glucose, insulin and feed 
data, where is pG accounts for both endogenous clearance 
and the net impact of endogenous glucose production on 
removal. This approach is used to create virtual patients [5-
7,9] to test protocols. Virtual trials use these profiles to 
determine patient specific blood glucose levels for different 
insulin and nutrition inputs. Hence, different protocols can 
be compared for the same patient, a significant advantage in 
developing and validating new protocols.   
The cohort used covers a general cross-section of ICU 
population, APACHE II score (Average: 21.8, Range: 8-36), 
age, sex and mortality [7]. Average stay is 3.9 days (Range: 
1.4-18.8 days). APACHE II scores are much higher than in 
[2, 3] and [4]. Hence, these patients are more critically ill 
and more insulin resistant.     
B. SPRINT Protocol 
SPRINT is based on a computerized protocol [5,9,10] 
that regulates both nutritional and insulin inputs. The 
permissible range of feed variation was 280-700kcal/day 
from glucose based on the ideal rate for an 80kg male. At 
the 280kcal/day minimum, the total caloric intake is still 
778kcal/day [11], which exceeds the level found to avoid an 
increased risk of bloodstream infections [12]. 
SPRINT is designed to provide an easy-to-use equivalent 
to a computerised protocol to enable long term clinical 
testing of the variable insulin and nutrition control approach. 
The protocols for controlling feed and insulin inputs were 
developed through virtual patient trials of the 19-patient 
cohort to maintain blood glucose levels within the 4-
6.1mmol/L band. The goal is equal glycaemic control to the 
computerised method by mimicking its actions [9,10].  
The SPRINT protocol consists of two wheels dedicated to 
enteral nutrition optimisation (specifically RESOURCE® 
Diabetic) and insulin bolus administration (Actrapid), and is 
shown in Figure 1. The starting criterion is blood glucose 
greater than 8.0mmol/L. The instructions on the “Feed 
Wheel” in Figure 1 are used to determine the rate of feed as 
a percentage of the patient’s clinically determined goal feed. 
The result is based on the previous hour’s feed level, the 
current blood glucose concentration and whether blood 
glucose is rising or falling. The percentage goal feed is 
converted into an absolute feed rate (in ml/hr) using a 
patient-specific conversion sticker. The “Insulin Wheel” is 
then used to determine the insulin bolus size based on the 
previous insulin bolus size, the current blood glucose level 
and whether the blood glucose has decreased by more than 
1.5mmol/L. Importantly, the method is effectively fully 
automated, aside from feed rate, as it relies on no other 
external clinical inputs or modifications for any patient. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: SPRINT insulin and feed wheels [9]. 
 
Hourly blood glucose measurements are used to ensure 
tight control. Two-hourly measurements are used when the 
patient is stable, defined as 3 consecutive measurements in 
the 4.0-6.1mmol/L. For two-hourly measurements, the feed 
rate is maintained constant, and the same insulin bolus is 
administered again on the hour between measurements. 
Two-hourly measurements are continued until the patient 
leaves the 4.0-6.1mmol/L band. SPRINT is stopped when 
the patient is stable, normoglycaemic, and adequately self 
regulating. This state is defined as 6 or more hours in the 4-
6.1mmol/L band, with over 80% of goal feed rate and a 
maximum of 2U/hr insulin. Finally, insulin is administered 
via bolus for safety, thus avoiding infusions being left on.  
The layout resulted from extensive consultation. Clinical 
staff reported the system as very easy to use. The covered 
wheel reduces complexity, reducing error. Overall, SPRINT 
is simple enough to integrate with any typical ICU practice.  
C. Virtual Trial Protocol Comparison 
Virtual trials are used to compareSPRINT with the 
published protocols from the landmark studies [3,4]. The 
computerised AIC4 protocol [5] provides another 
comparison. Protocols that used glucose shots for 
hypoglycaemia, were modelled at the same value and 
administered over 5 minutes. No other changes were made 
from the published protocols. Performance is measured by 
 
 
 
time spent in the 4-6.1mmol/L band [3], or the 4-7.75 
mmol/L [4] band, rather than a simple average value [13]. 
Hence, glycaemic levels and the tightness with which they 
are maintained are both assessed for a more complete 
analysis of the efficacy.  
The simulation approach is Monte Carlo based. Each 
protocol is run 20 times for all 19 virtual patients including 
random measurement errors. The results are stored for every 
glucose measurement the specific protocol required, rather 
than reporting a morning average or other surrogate. Finally, 
to validate the comparison and design approach SPRINT 
clinical results are compared with the simulation results. 
III. VIRTUAL TRIALS RESULTS 
Table 1 shows the virtual trial results for SPRINT, the 
computerized AIC4 protocol that it  mimics, and the two 
landmark clinical protocols. The clinical protocols are 
denoted by lead author as “Krinsley” for [4] and “vdB” for 
[3]. The glucose results in all cases are lognormal (p < 
0.005), instead of the often assumed normal distribution. 
The 68.3% and 95.5% ranges thus represent 1 and 2 
multiplicative standard deviations respectively. The time in 
band values are percentages of the total trial time. The 
average insulin and average percentage of goal feed are 
presented to show the level of interventions.  
 
Table 1: Virtual clinical trial results 
 SPRINT Krinsley [4] vdB [3] AIC4 [5] 
50th Percentile 5.79 8.59 5.60 5.93 
Mult. STD 1.29 1.29 1.65 1.35 
68.3% range (4.5-7.5) (6.7-11.1) (3.40-9.24) (4.4-8.0) 
95.5% range (3.5-9.6) (5.2-14.2) (2.1-15.2) (3.3-10.8) 
Time in 4-6.1  61.7% 11.2% 35.8% 62.2% 
Time in 4-7.75  83.5% 27.4% 51.0% 82.9% 
Time < 4 4.4% 0.6% 23.6% 1.1% 
Time > 7.75 12.1% 72.0% 25.3% 16.1% 
Avg insulin (U/hr) 2.4 1.6 3.0 2.6 
Avg % goal feed  61.9% 67.7% 67.7% 75.8% 
 
Note that the percentage of goal feed values are all less 
than 100% as the retrospective data contains clinical 
stoppages of feed for other clinical causes. The feed levels 
used are based on the retrospective patients goal feed and 
the type of enteral or TPN nutrition reported for the given 
study, which is typically 50% of calories from dextrose as 
opposed to the 35% for the enteral feed used in this clinical 
study.  
The noticeable outlying protocol was from [4], however it 
is less intensive with a target average of 7.75 mmol/L. The 
50th percentile blood glucose levels for SPRINT and AIC4 
are comparable with the [2, 3]. However, the 95.5% range of 
3.50-9.58 mmol/L, compared to Leuven’s to 2.06-15.24 
mmol/L from the Leuven study, shows much tighter control, 
with similar results over the 68.3% range. Thus, SPRINT 
and its computerized version (AIC4) tightly regulate blood 
glucose without significant risk of hypoglycaemia.  
The results also compare well with reported average 
values, suggesting that the computer simulation method 
produced realistic results. Differences, such as the 2.7% of 
measurements below 2.2 mmol/L in the simulated Leuven 
protocol compared to 1.0% in the reported results [2, 3], 
may be due to a more severely ill patient cohort here. 
Specifically, this virtual cohort has an average APACHE II 
score of 21.8 versus 9 for the Leuven protocol [2,3] and 16 
for the Krinsley protocol [4]. Overall, the results are 
qualitatively similar to the reported values adding weight to 
these simulation results. 
Another difference may be due to the assumptions made 
where the protocols referred to specialized clinical input. 
The insulin dosages recommended by the Leuven protocol 
were intended as “directives, rather than strict numerical 
instructions” [3]. Insulin dose adjustments in the Leuven 
study were also guided by factors, such as body temperature 
and infection. Retrospective data for these parameters were 
not available for simulation and the protocol was run on a 
strict numerical basis, with insulin doses capped at 15 U/hr. 
The advantage of the AIC4 and SPRINT protocols, in all 
cases, is that they are essentially fully automated.  
IV. CLINICAL VALIDATION RESULTS 
Figure 2 shows probability density functions for clinical 
SPRINT results over the first 90 patients and ~13,000 hours, 
as compared to the SPRINT and AIC4 simulations for 
comparison. The clinical cohort has an average APACHE II 
score of 21 and an average length of stay on SPRINT of 
~130 hours. The similarity of SPRINT and AIC4 is expected 
as SPRINT mimics the target based, computerized AIC4 
controller. Figure 2 also shows simulated results for the van 
den Berghe et al [2,3] and Krinsley [4] protocols. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Probability density functions based on both virtual and clinical 
glycaemic control trial results 
 
Overall, the results in Figure 2 show two main results. 
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First, the simulated and clinical SPRINT results are very 
close, particularly with respect to their width through the 
4.0-6.1 mmol/L and 4.0-7.75 mmol/L tight control ranges. In 
particular, they are tighter through these ranges and overall 
than the more strongly lognormal results from the protocols 
used by van den Berghe et al and Krinsley. Second, the 
simulated and clinical SPRINT results are very close with 
the gaps representing less than 10% of all measurements for 
the simulated results to be outside the clinical results. Hence, 
comparing simulation and clinical results indicates that the 
virtual trial simulation approach is both accurate and slightly 
conservative when deciding to implement them clinically. 
In the low and hypo- glycaemic ranges there are 
significant differences comparing SPRINT results to other 
protocols. The van den Berghe protocol has 3.5% of 
measurements below 2.5 mmol/L in comparison to 0.1% for 
clinical SPRINT results and 0.16% for virtual trial SPRINT 
results. Below 4.0 mmol/L, the results are 23.6% for the van 
den Berghe protocol versus 2.6% for clinical SPRINT and 
0.6% for Krinsley’s protocol. 
With regard to high blood glucose levels there are also 
significant differences due to the differing levels of tight 
control achieved. Specifically, 25.3% of the van den Berghe 
protocol results are above 7.75 mmol/L versus 10% for 
SPRINT and 70% for the more conservative protocol used 
by Krinsley. Note that of the 10% above 7.75 mmol/L from 
SPRINT 2% occur in the first 12-24 hours of use due as the 
initially elevated blood glucose levels are reduced. 
V. DISCUSSION 
The variable nutrition and insulin approach presented is 
shown to be highly effective at tightly controlling blood 
glucose levels. Both of these protocols were developed 
using the virtual trial method and the virtual patient cohort 
presented in this work. The SPRINT table based version and 
the computerized AIC4 method it mimics also deliver very 
similar results, further validating the approach.  
 The overall data analysis presented is statistically valid, 
however there may be some differences in the protocols 
modeled for the Leuven and Krinsley protocols. Differences 
are largely due to the lack of complete published protocol 
information. In particular, both protocols use additional data 
and can rely on unspecified, patient specific clinical 
modification of treatment that is not reported.  
In contrast, the SPRINT and AIC4 protocols are 
effectively fully automated. In all clinical studies, neither 
SPRINT nor the AIC4 protocol required any clinical 
modification. Thus, the only patient specific aspect is the 
goal feed level [5,9,10] and protocols are otherwise used 
identically for all patients, unlike other published results. 
VI. CONCLUSIONS 
There are two main results from this work. First, the 
virtual patient simulation and design approach is presented 
and validated as an effective means of developing clinical 
protocols for tight glycaemic control. The results when 
implemented clinically are shown to be, for the cases 
presented, very close to reported clinical results, with 
differences attributable to differences in patient cohort and 
level of critical illness. Second, the variable insulin and 
nutrition approach, as seen with the SPRINT protocol, 
provides a long term and stable method of tightly controlling 
blood glucose for a very critically ill cohort and over very 
long periods of stay. Finally, the approach is seen to be 
slightly conservative in making clinical implementation 
decisions from the simulated virtual trials. 
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